Clinical trials: Depression in Schizophrenia
Schizophrenia, Psychotic Disorders
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
This is a randomized, single-dose, open-label, parallel-group study. Patients will undergo the screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- NCT05321602
- Testing
- LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid
- Where
- 9 sites in United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Psychotic Disorders, Anxiety Depression
Effects of Online and Recovery-oriented Peer Support Groups Facilitated by Peer Support Workers in Times of COVID-19
In times of pandemics, social distancing, isolation and quarantine exacerbate depression and anxiety as confined people are detached from their loved ones, deprived of personal liberties, and devoid of purpose owing to altered…
- Trial name
- NCT04445324
- Testing
- Transitional Online Peer Support Group (n=20), Control Group (pharmacotherapy and/or psychotherapy, n=10)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal
Schizophrenia
Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy Subjects
GSK1144814 is a potent, insurmountable antagonist at human neurokinin-1 (NK1) and neurokinin-3 (NK3) receptors with the potential to treat multiple symptom domains of schizophrenia and be an efficacious antidepressant.
- Trial name
- MNK112891 (NCT01090440)
- Testing
- GSK1144814
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Chronic Kidney Diseases
The Multi-Ethnic Lifestyle Study
The study design is cross-sectional using a self-completion questionnaire in an English speaking multi-ethic population within Leicester and Leicestershire.
- Conditions
- Diabetes Mellitus, Chronic Kidney Diseases, Cardiovascular Diseases, Obstructive Sleep Apnea
- Trial name
- MELS (NCT04256720)
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 9,500 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Cognitive Therapy
Exploring the Effectiveness of Group Cognitive Stimulation Therapy in People With Schizophrenia.
Background: Cognitive dysfunction is the core defect of schizophrenia, which seriously affects the emotional, social functions and quality of life in people with schizophrenia.
- Trial name
- NCT04916483
- Testing
- group cognitive stimulation therapy, usual care
- Where
- Taiwan
- Volunteers
- 90 people
- Sponsor
- National Yang Ming Chiao Tung University
Schizophrenia, Schizoaffective Disorder
Thinking Skills for Work in Severe Mental Illness
The purpose of this study is help people with serious mental illness and receiving vocational rehabilitation get and keep the job they want by improving their thinking skills, such as attention and memory, using computer…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder
- Trial name
- TSW (NCT01926613)
- Testing
- Thinking Skills for Work Program, Supported Employment
- Where
- 2 sites in United States
- Volunteers
- 110 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Psychotic Disorders, Autism Spectrum Disorder
EEG Microstates Across At-Risk Mental States
The goal of this observational study is to compare subjects with at-risk-mental-state, early psychosis, schizophrenia, depression, and autism spectrum disorders, with healthy controls (N = 21 x 6).
- Conditions
- Psychotic Disorders, Autism Spectrum Disorder, Major Depressive Disorder, Schizophrenia
- Trial name
- DEMETER (NCT06045897)
- Testing
- EEG 64 channels, Polysomnography 19 electrodes, Light hypnosis
- Where
- France
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier St Anne
Mental Health Impairment
Pharmacogenetic Supported Prescribing in Kids
Implementation of pharmacogenetic testing for children and adolescents aged 6-24 who are starting or changing psychiatric medication.
- Trial name
- PGx-SParK (NCT04797364)
- Testing
- Pharmacogenetic Testing
- Where
- Canada
- Volunteers
- 6,000 people
- Sponsor
- University of Calgary
Schizophrenia, Depression
Regulation of Arginine-vasopressin (AVP)
This study aims to develop a method for the assessment of central NMDA receptor functioning in patients with depression and schizophrenia.
- Trial name
- REGAVP (NCT02626832)
- Testing
- Procedural
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Yale University
Depressive Disorder, Major, Bipolar Disorder
In-person vs. Remote Wellness Support
The study team will use components of the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) framework to compare Cognitive Adaptation Training (CAT) to Remotely delivered Cognitive Adaptation Training (R-CAT)…
- Conditions
- Depressive Disorder, Major, Bipolar Disorder, Schizo Affective Disorder, Schizophrenia
- Trial name
- R-CAT (NCT04526067)
- Testing
- CAT, R-CAT
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Suicidal Behaviour, Cognitive Functions Confusion
Analysis of Parameters Indicating the Intensity of Suicidal Behavior in Psychiatric Patients
The aim of this study was to analyse the level of cognitive functioning of patients with history of suicidal behaviour suffering from depression and schizophrenia, and to evaluate their oxidative stress parameters and selected…
- Trial name
- NCT05803447
- Testing
- Interview questionnaire, biochemical parameters, cognitive function
- Volunteers
- 120 people
- Sponsor
- Medical University of Bialystok
Schizophrenia Disorders, Major Depression
Non-Coding RNAs Gene Expression in Psychiatric Disorders
This study aims to investigate whether specific non-coding RNAs, molecules involved in the regulation of gene expression, are altered in individuals with psychiatric disorders such as schizophrenia, bipolar disorder, major…
- Conditions
- Schizophrenia Disorders, Major Depression, Bipolar Affective Disorders, Obsessive Compulsive Disorder (OCD)
- Trial name
- PsiRNA26 (NCT07649993)
- Testing
- Reverse Transcription Quantitative Polymerase Chain Reaction
- Where
- 5 sites in Italy
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- Carmen Concerto
Psychiatric Disorders (Diagnosis)
Contribution of Virtual Reality Eye Tracking in the Identification of Schizophrenia, Bipolar and Depression
Schizophrenia (SCZ), bipolar disorder (BP), and depression (DEP) are systematically associated with a severe impairment of the overall abilities of patients, which precludes them from functioning adequately in daily life.
- Trial name
- ReViPSY (NCT07057024)
- Testing
- Clinical and eye movements
- Where
- France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Etablissement Public de Santé Barthélemy Durand
Schizophrenia, Depression
Neuromodulation in Depressed and Schizophrenic Patients - Changing MEP (Muscle Evoked Potentials) by tDCS (Transcranial Direct Current Stimulation)
Muscle evoked potentials (MEP) are supposed to different in schizophrenic and depressed patients, compared to a sample of healthy volunteers.
- Trial name
- NCT01150734
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Ludwig-Maximilians - University of Munich
Schizophrenia
Four Dimensions in Schizophrenia
Observational, non-interventional, longitudinal, prospective,multicenter, open label (No treatment is involved). 4 assessment will be carried out , in months 0, 1, 3 and 6.
- Trial name
- 4D (NCT00782899)
- Where
- 65 sites in Spain
- Volunteers
- 320 people
- Sponsor
- AstraZeneca
Randomized Controlled Trial
Exploring the Effect of Rumination-Focused Cognitive Behaviour Therapy in Patients With Schizophrenia
This study will explore the effect of Rumination-Focused Cognitive Behaviour Therapy on depressive symptoms in patients with schizophrenia for three months.
- Trial name
- NCT04442893
- Testing
- Rumination-Focused Cognitive Behaviour Therapy, Health Education programme
- Where
- Taiwan
- Volunteers
- 85 people
- Sponsor
- National Yang Ming Chiao Tung University
Metabolic Syndrome, Quality of Life
Prevalence of and Factors Associated With Metabolic Syndrome in Schizophrenia
Patients with schizophrenia are more likely to have metabolic syndrome compared to general population. The criterion for metabolic syndrome in Asian people including: elevated waist circumference (male ≥ 90cm, female ≥ 80cm)…
- Conditions
- Metabolic Syndrome, Quality of Life, Depression
- Trial name
- NCT01587521
- Where
- Thailand
- Volunteers
- 80 people
- Sponsor
- Chiang Mai University
Psychotic Disorders, Schizophrenia
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
The purpose of this study is to gather information about the steady-state plasma concentrations of aripiprazole, olanzapine, quetiapine and their relevant metabolites, at various dose levels and at different time points after…
- Conditions
- Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
- Trial name
- NCT02087579
- Testing
- Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation
- Where
- 24 sites in United States, Argentina and 5 more
- Volunteers
- 305 people
- Sponsor
- Janssen Research & Development, LLC
Psychiatric Disorders, Depression - Major Depressive Disorder
Implementing Action-Based Cognitive Remediation for Transdiagnostic Cognitive Difficulties in a Tertiary Mental Health Hospital
Psychiatric conditions are each defined by different set of symptoms, however, they often share common characteristics such as impairments in cognitive and social functioning.
- Conditions
- Psychiatric Disorders, Depression - Major Depressive Disorder, Schizophrenia and Other Psychotic Disorders, Anxiety and Mood Disorders
- Trial name
- NCT07506070
- Testing
- Action-Based Cognitive Remediation
- Volunteers
- 160 people
- Sponsor
- The Royal Ottawa Mental Health Centre
Bipolar Disorder, Schizophrenia
Life Goals Collaborative Care to Improve Health Outcomes in Mental Disorders
Persons with serious mental illness (SMI) are at increased risk of cardiovascular disease (CVD). The goals of this study are to test a treatment, Life Goals Collaborative Care to help promote health behavior change and improve…
- Conditions
- Bipolar Disorder, Schizophrenia, Major Depressive Disorder, Schizoaffective Disorder
- Trial name
- NCT01487668
- Testing
- Life Goals Collaborative Care
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- VA Office of Research and Development